A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
PHASE3
The study objectives of Period 1 of this study were to compare the efficacy...
Status
Completed
Location
Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 152964
Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.
PHASE2
The goal of this multicenter, randomized, double-blind, placebo-controlled ...
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
PHASE3
The primary objectives of this study are to compare the efficacy, safety, a...